August 2026 · Real-world oncology task · Verified claim

MELANOMA 1L BRAF+

First-line regimen choice for BRAF V600-mutant advanced melanoma on IBM Heron r2 · ibm_kingston · 156 qubits — a pre-registered multi-logic expectation, scored PASS on raw QPC readout.

Plain English

What this task is: A patient already has unresectable or metastatic melanoma with a BRAF V600 mutation. A melanoma oncologist must choose a first-line systemic regimen. This is drug selection after diagnosis — not mole examination.
What we expected (locked before the run): Nivolumab + ipilimumab must outrank nivolumab + relatlimab on QPC multi-logic priority — because mono-efficacy says so, while a simple equal-weight average says the opposite (the gentler PD-1/LAG-3 pair wins on safety and schedule).
What QPC computed: One coupled quantum job on ibm_kingston (Heron r2, 156Q) · 18-qubit desk · 4096 shots · raw counts primary · public job ID below.
Headline result: PASS — nivo+ipi priority 0.569 > nivo+rela 0.394. The claim was verified.
What this delivers: A verified ranking on frozen public landmark-trial proxies under co-resident efficacy, safety, and treatment burden. Architecture research — not a prescribing tool.

Verdict

PASS — expectation MEL-1L-E1 verified

QPC ranked nivolumab + ipilimumab above nivolumab + relatlimab on coupled raw multi-logic priority, against equal-weight classical on the same proxies.

PASS

Claim verdict

0.569

Nivo+ipi priority

0.394

Nivo+rela priority

+0.175

Margin

Why this counts as a real result

Same indication, same chooser: 1L unresectable/metastatic BRAF V600+ melanoma.
Five approved alternatives a melanoma oncologist actually chooses among.
Expectation written and locked before IBM submit.
Classical methods disagree on the pair (mono-efficacy vs equal-weight).
Success = claim verified on raw coupled counts.

Method	Order on the pair
Mono-efficacy	nivo+ipi > nivo+rela
Equal-weight average	nivo+rela > nivo+ipi
QPC coupled raw (this job)	nivo+ipi > nivo+rela — PASS

Full QPC ranking (1L BRAF+ panel)

Rank	Regimen	Priority
1	pembrolizumab	0.595
2	nivolumab + ipilimumab	0.569
3	encorafenib + binimetinib	0.560
4	nivolumab + relatlimab	0.394
5	dabrafenib + trametinib	0.377

The locked claim is the pair only (nivo+ipi vs nivo+rela). The table is the full coupled readout on the frozen panel.

Job record

Field	Value
Backend	IBM Heron r2 · `ibm_kingston` · 156 qubits
Job ID	`da1gvd6g52gs73clkp20`
Shots	4096
Geometry	5 regimens × 3 logics + 3 junctions = 18 qubits
Primary metric	MEL-1L-E1 claim verdict on coupled raw priority
Label	Architecture research on frozen public trial proxies — not a prescribing tool

MELANOMA 1L BRAF+

Verdict

Why this counts as a real result

Classical contrast (same proxies)

Full QPC ranking (1L BRAF+ panel)

Job record